drugset / Trial / NCT04225208

Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Volunteers

NCT04225208

Phase 1 Completed 8 enrolled Dizal Pharmaceuticals
NaSingle-groupOpen-labelOther

Summary

This is a phase I, open label, healthy volunteers, ADME study with single oral administration of \[14C\]-AZD4205.

Timeline

Start
2020-01-06
Primary completion
2020-03-02
Completion
2020-03-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Golidocitinib Small molecule 50 mg Oral

Indications

No indication recorded.